Welcome : Guest

Rigel Pharmaceuticals, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Rigel Pharmaceuticals, Inc., which is principally a Clinical-Stage Drug Development Company. Illustrated with 69 tables, the report showcases the company's recent news stories and events, key markets and market position as against its competitors operating in the industry.

Code: PCP-10119
Price: $3450
Company Type: Public
Pages: 71
Date: November 2016
Market Data Tables: 69

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Dermatological Drugs......2
Table 1: Dermatological Drug Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Acne, Alopecia, Atopic Dermatitis, Herpes, Psoriasis, Rosacea, Skin Cancer, and Skin Infections......2
Table 2: Dermatology Drugs Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for France, Germany, Italy, Japan, Spain, UK, US, and Rest of World......3
Table 3: Dermatology Market by Category in the US (2015) - Percentage Share Breakdown by Value for Genericised, Off-Patent but No Generics, On-Patent, and Others......4
Table 4: Dermal Substitutes Chronic Wound Market by Category in the US (2015) - Percentage Share Breakdown by Value for Diabetic Foot Ulcer, Pressure Ulcer and Venous Leg Ulcer......5
Table 5: Prevalence & Severity of Actinic Keratoses Market by Category in the US (2015) - Percentage Share Breakdown by Value for Minimal, Moderate, Severe, and Others......6
Asthma Drugs......7
Table 6: Asthma Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for Europe, North America and Rest of the World......7
Table 7: No. of Asthma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Europe, North America, and Rest of World......8
Table 8: Asthma Drugs Market by Product Segment in the US (2015) - Percentage Share Breakdown by Value for Advair Diskus, Combivent, Proair HFA, Singulair, Spiriva HandiHaler, Symbicort, and Others......9
Cancer Drugs......10
Table 9: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......10
Table 10: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......11
Cancer Market......12
Table 11: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......12
Table 12: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......13
Table 13: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......14
Table 14: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......15
Table 15: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......16
Table 16: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......17
Table 17: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......18
Table 18: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......19
Cancer Patients......20
Table 19: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......20
Table 20: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......21
Table 21: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......22
Table 22: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......23
Table 23: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......24
Table 24: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......25
Table 25: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......26
Table 26: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......27
Table 27: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......28
Table 28: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......29
Table 29: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......30
Table 30: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......31
Table 31: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......32
Table 32: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......33
Table 33: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......34
Table 34: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......35
Table 35: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......36
Table 36: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......37
Table 37: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......38
Table 38: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......39
Table 39: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......40
Cervical Cancer......41
Table 40: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......41
Table 41: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......42
Hematological Cancer......43
Table 42: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......43
Skin Cancer......44
Table 43: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......44
Cancer-Associated Mucositis......45
Table 44: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......45
Chronic Myelogenous Leukemia (CML)......46
Table 45: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......46
Multiple Myeloma......47
Table 46: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......47
Table 47: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......48
Immunotherapy......49
Table 48: No. of Patients for Immunotherapy by Region Worldwide (2015) - Percentage Market Share Breakdown by Value for Europe, North America, and Others......49
Table 49: Immunotherapy Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union, United States and Rest of the World......50
Table 50: Immunotherapy Market by Type Worldwide (2015) - Percentage Share Breakdown by Value for Subcutaneous, and Sublingual......51
Table 51: No. of Patients for Immunotherapy by Age Group in the US (2015) - Percentage Market Share Breakdown by Value for 0-4 Patient Pool, 10 - 14 Patient Pool, 15 - 19 Patient Pool, 5-9 Patient Pool, Adult Patient Pool (over 65), and Adult Patient Pool (under 65)......52
Table 52: Allergy Immunotherapy Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for Europe, France, Germany, Italy, Spain and Others......53
Table 53: Grass Allergy Immunotherapy Treatment by Segment in Germany (2015) - Percentage Breakdown by No. of Patients for Subcutaneous, Sublingual, and Tablet......54
Table 54: Grass Allergy Immunotherapy Treatment by Type in Germany (2015) - Percentage Breakdown by No. of New Patients for Subcutaneous, and Sublingual......55
Immunology......56
Table 55: Immunology Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Dermatology, Gastroenterology, and Rheumatology......56
Dermatological Products......57
Table 56: Market Shares of Leading Dermatological Product Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Johnson & Johnson, Pfizer, Inc., Reckitt Benckiser Plc, and Others......57
Table 57: Market Shares of Leading Dermatology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Biogen Idec, Inc., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, and Others......58
Table 58: Market Shares of Leading Therapeutic Dermatology (excluding Aesthetics) Medicine Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Inc. (ABBV), Galderma S.A., GlaxoSmithKline Plc (GSK), Johnson & Johnson, Merck & Co., Inc. (MRK), Pfizer, Inc. (PFE), Amgen, Inc. (AMGN), Valeant Pharmaceuticals Intl, Inc., Dermik Laboratories, and Others......59
Table 59: Market Shares of Leading Drugs for Treatment of Skin Infection in the US (2015) - Percentage Share Breakdown by Value for CUBICIN, VANCOMYCIN, ZYVOX IV and Others......60
Cancer Drugs......61
Table 60: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......61
Table 61: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......62
Table 62: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......63
Table 63: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......64
Table 64: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......65
Breast Cancer Drugs......66
Table 65: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......66
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......67
Table 66: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......67
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......68
Table 67: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......68
Table 68: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......69
Table 69: Rigel Pharmaceuticals, Inc.’s Sales by Business Segment Worldwide (2013) in Percentage for AstraZeneca and Daiichi Sankyo......70